B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11

Benzinga · 2d ago
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.